Core Viewpoint - A class action lawsuit has been filed against agilon health, inc. for allegedly misleading investors about its business prospects and failing to disclose material industry challenges [1][2]. Group 1: Allegations and Company Performance - The complaint alleges that agilon health, inc. issued unrealistic guidance for 2025, knowing it was unlikely to be achieved due to significant industry headwinds [2]. - The company reportedly overstated the immediate financial benefits from strategic actions taken to mitigate risks [2]. - Following the announcement of disappointing financial results and the resignation of CEO Steven Sell on August 4, 2025, agilon's stock price plummeted over 50%, closing at $0.8801 on August 5, 2025 [3]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers by March 2, 2026, to represent the class in the litigation [4]. - Shareholders can remain absent class members and still be eligible for recovery without participating in the case [4]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless a recovery is achieved [5].

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of all persons or entities who purchased or otherwise acquired Agilon Health, Inc. (“Agilon” or the “Company”) (NYSE: AGL) securities between February 26, 2025, and August 4, 2025. The Complaint alleges that (i) Defendants recklessly issued guidance for 2025 that they knew or should have known ...

Core Viewpoint - A federal securities class action has been filed against Agilon Health, Inc. for alleged securities fraud during the class period from February 6, 2025, to August 4, 2025, with a deadline for investors to seek lead plaintiff status by March 2, 2026 [1][2]. Group 1: Legal Action - The complaint alleges that Agilon and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Agilon shares during the specified class period are eligible to join the class action [1]. Group 2: Market Reaction - Following the announcements made on August 4, 2025, Agilon's stock price fell by $0.94 per share, representing a 51.52% decline, closing at $0.88 on August 5, 2025 [3]. Group 3: Company Leadership and Financial Update - Steven Sell has stepped down as President, CEO, and Board Director of Agilon [7]. - The company reported its Q2 2025 results, with the Executive Chair noting that industry headwinds were "more acute than previously expected" [7]. - Agilon has suspended its full-year 2025 financial guidance due to these challenges [7].

Core Viewpoint - A class action lawsuit has been filed against Agilon Health, Inc. concerning allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline to apply as Lead Plaintiff by March 2, 2026 [2]. - The lawsuit pertains to actions taken by Agilon and certain officers and/or directors during the Class Period [2]. Group 2: Company Performance and Management Changes - On August 4, 2025, Agilon announced the resignation of Steven Sell as President, CEO, and Director of the Board [4]. - The same day, Agilon reported its second-quarter financial results, indicating that industry challenges were more severe than anticipated, leading to the suspension of its full-year 2025 financial guidance [4]. - Following these announcements, Agilon's stock price dropped by $0.94 per share, or 51.52%, closing at $0.88 per share on August 5, 2025 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. due to alleged violations of federal securities laws, encouraging affected investors to come forward and discuss their legal options [2][4]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the March 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against agilon health [2]. - The complaint alleges that agilon health and its executives made false and misleading statements regarding the company's financial guidance and performance, which led to significant investor losses [4]. - The lawsuit claims that when the true details about the company's financial situation became public, investors suffered damages, particularly following a 51.5% drop in stock price on August 5, 2025, after the company suspended its full-year 2025 financial guidance [5]. Group 2: Company Background and Contact Information - Faruqi & Faruqi, LLP has a history of recovering hundreds of millions of dollars for investors since its founding in 1995, with offices in multiple states [3]. - The firm encourages anyone with information regarding agilon health's conduct, including whistleblowers and former employees, to contact them for further investigation [7].

Core Viewpoint - A class action lawsuit has been filed against Agilon Health, Inc. for allegedly making false and misleading statements regarding its financial guidance and business operations during the Class Period from February 26, 2025, to August 4, 2025 [3][7]. Allegation Details - The lawsuit claims that defendants issued guidance for 2025 that they knew or should have known was unattainable due to significant industry challenges [3]. - It is alleged that defendants overstated the immediate positive financial impact from strategic actions taken to mitigate risks [3]. - As a result, statements made about Agilon's business, operations, and prospects were materially false and misleading throughout the Class Period [3]. Next Steps - Investors who purchased Agilon shares and suffered losses are encouraged to contact the law firm for more information regarding their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is March 2, 2026 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation, including securities and commercial cases [5]. - The firm operates nationwide and handles cases in both federal and state courts [5].

SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired agilon health, inc. (NYSE: AGL) securities between February 26, 2025 and August 4, 2025. Agilon describes itself as the "trusted partner empowering physicians to transform health care in our communities." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is I ...

NEW YORK--(BUSINESS WIRE)---- $AGL #AGL--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against agilon health, inc. ("agilon†or the "Company†) (NYSE: AGL) and reminds investors of the March 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has. ...

Core Viewpoint - A class action lawsuit has been filed against Agilon Health, Inc. for alleged violations of securities laws, specifically related to misleading statements made by the company regarding its financial guidance and strategic actions [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Agilon's securities between February 26, 2025, and August 4, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Agilon - The complaint alleges that Agilon made false and misleading statements to the market, particularly regarding its 2026 guidance, which was deemed unrealistic [4]. - The company is accused of overstating the effectiveness of its strategic actions aimed at reducing risk, leading to materially misleading public statements throughout the class period [4]. - As a result of the revelations about Agilon's true situation, investors reportedly suffered financial damages [4].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of agilon health, inc. securities for the period between February 26, 2025, and August 4, 2025, due to alleged misleading statements and guidance by the company [1][5]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false and/or misleading statements regarding agilon's financial guidance for 2025, which they knew or should have known was unattainable due to industry challenges [5]. - It is alleged that the defendants overstated the positive financial impact from strategic actions taken by agilon to mitigate risks, leading to materially false statements about the company's business and prospects [5]. - Investors are encouraged to join the class action, which allows them to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4]. - Investors can join the class action by submitting a form or contacting the firm directly for more information [3][6].